A brief look at some of ICGEB’s more recent, top research articles published in the last quarter of 2022.
In October 2022: an antibody isolated from people in India who recovered from COVID-19 was found to broadly neutralise SARS-CoV-2 variants, including Omicron sub-lineages. The ICGEB-Emory Group at ICGEB, New Delhi discovered a unique human monoclonal antibody that potently neutralises all key SARS-CoV-2 variants and sub-lineages of Omicron. This study was published in the October issue of the scientific journal Science Advances, and commented in Nature India.
Dr. Anmol Chandele, last author, comments
*
Published in Blood: Dr. Dimitar Efremov and the Molecular Hematology Group report latest results on human Richter Syndrome.
*
Published in Nature Microbiology: Dr. Vittorio Venturi, Bacteriology lab, reports on biocontrol by plant-beneficial Pseudomonas.
*
Published in the Chemical Engineering Journal: Dr. Naseem Gaur, Yeast Biofuel Group, New Delhi, considering the economic viability of generating “green biocatalysts”reports on the tailored designing of a diploid S. cerevisiae natural isolate for increased production of fatty acid ethyl ester.
*
Published in mBio: Dr. Lawrence Banks, and first author Dr. Om Basukala, Tumour Virology lab, publish a study in the American Society for Microbiology journal that has important implications for the molecular basis of the Human papillomavirus (HPV) E7 function in modulating protein trafficking at the cell surface
*
Work by Prof. Serena Zacchigna and the Cardiovascular Biology lab makes the cover of the November edition of Trends in Pharmacological Sciences for work on Biologics and cardiac disease: challenges and opportunities.
